IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 45 filers reported holding IMPEL NEUROPHARMA INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,755 | -80.1% | 178,500 | -41.2% | 0.04% | -79.4% |
| Q2 2023 | $385,578 | -28.1% | 303,605 | -20.8% | 0.20% | -37.8% |
| Q1 2023 | $536,410 | -56.1% | 383,148 | +17.6% | 0.33% | -60.3% |
| Q4 2022 | $1,221,844 | -46.5% | 325,825 | -30.6% | 0.83% | -44.0% |
| Q3 2022 | $2,285,000 | -44.1% | 469,183 | +7.0% | 1.48% | -39.4% |
| Q2 2022 | $4,087,000 | +74.8% | 438,566 | +19.5% | 2.43% | +137.7% |
| Q1 2022 | $2,338,000 | +5.8% | 367,058 | +43.4% | 1.02% | +14.3% |
| Q4 2021 | $2,210,000 | +21.0% | 256,027 | +70.7% | 0.90% | +11.2% |
| Q3 2021 | $1,827,000 | – | 150,000 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NVP Associates, LLC | 3,077,198 | $11,539,493 | 11.26% |
| Vivo Capital, LLC | 2,884,789 | $43,272 | 4.98% |
| venBio Partners LLC | 2,759,791 | $10,349,216 | 3.21% |
| 5AM Venture Management, LLC | 2,884,791 | $10,817,966 | 2.91% |
| LASRY MARC | 408,329 | $1,531,234 | 2.38% |
| DCF Advisers, LLC | 325,825 | $1,221,844 | 0.83% |
| Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $15,509,891 | 0.52% |
| EPIQ PARTNERS, LLC | 18,646 | $69,923 | 0.05% |
| J. Goldman & Co LP | 200,219 | $750,821 | 0.04% |
| MCDONALD PARTNERS LLC | 11,700 | $43,875 | 0.02% |